-
Mashup Score: 9A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM - 2 month(s) ago
Original Article from The New England Journal of Medicine — A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3More Pediatric Patients with NASH, NAFLD are Male, Hispanic than Adult Patient Population - 6 month(s) ago
An analysis of age-stratified fatty liver disease patient demographics show a surprising shift in racial/ethnic and sex trends among children and adolescents.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1
HU6 could be a promising pharmacological agent for treating patients with obesity and NAFLD and its metabolic complications.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 2
HU6 could be a promising pharmacological agent for treating patients with obesity and NAFLD and its metabolic complications.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Patients with NASH, T2D Face Costly Financial Burden - 6 month(s) ago
Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Efruxifermin in non-alcoholic steatohepatitis - 6 month(s) ago
Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the commonest causes of liver-related mortality and morbidity, with a predicted global prevalence of 30%.1 This finding has fuelled extensive therapeutic research; however, there are no currently licensed therapies for NAFLD, with weight loss and lifestyle interventions as the mainstay of treatment.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 10NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis - 6 month(s) ago
Tissue resident γδ T cells mediate the transition from steatosis to steatohepatitis in metabolic-associated fatty liver disease.
Source: www.science.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Noninvasive ABDA Score Predicts Fibrotic NASH - 6 month(s) ago
Investigators developed the identification model based on significantly associated factors of fibrotic NASH and tested it in derivation and validation cohorts, where it identified 89.9% and 81.0% of patients with fibrotic NASH, respectively.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 03 Agents to Watch for Decompensated Cirrhosis from NASH - 6 month(s) ago
HepaStem, BIV201, and Albutein are late-stage pipeline agents in development for NASH, focusing specifically on decompensated cirrhosis.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Home - 7 month(s) ago
The incidence of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), continues to rise globally along with an increase in obesity, type 2 diabetes, and other metabolic disorders. Patients at risk of MASH greatly benefit from early identification and intervention. Join us at this interactive, case-based symposium where you can see how your case management strategies compare with those of your peers. Don’ t miss out! This activity is intended for
Source: na.eventscloud.comCategories: Dermatology, Latest HeadlinesTweet
Surprising result! A thyroid hormone receptor β (THR-β) agonist appears effective in improving #NASH. Decreased THR-β activation promotes NASH by "reducing mitochondrial function and β-oxidation of fatty acids" which ultimately leads to fibrosis. https://t.co/uDFoY6XLPu